LOUISVILLE, CO--(Marketwire - December 19, 2007) - GlobeImmune, Inc. announced today the initiation of the Company’s Phase 2 clinical trial to evaluate GI-5005 Tarmogen® for the treatment of patients with chronic hepatitis C infection. GI-5005 is being evaluated as a potential therapy in combination with standard of care, pegylated interferon plus ribavirin.
